Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.

In addition, two months ago, Alcon secured a majority stake in clinical-stage company Aurion Biotech. In February, Alcon reported 2024 revenue at $9.8 billion, which was up 5% from the prior year.

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...

Ask Comptroller Brad Lander about housing, and it is only a matter of time before he brings up the Gowanus rezoning. That’s because he sees the 2021 rezoning as a model for other neighborhoods ...

Some drivers might appreciate the Camry's soft and unengaging demeanor, but anyone who expects the TRD trim to be a sport sedan will be disappointed. Despite not offering a powerful V-6 like the ...

The company will enter a category with a number of existing players, including Novartis/Intellia, Genentech/Lineage Cell Therapeutics, and Aurion Biotech, amongst others. The Series A has been ...

At close: May 26 at 11:02:28 AM EDT ...

Supercharged V6, 3.5L, Premium Unleaded Petrol, 6 Speed Automatic ...

Today, a brief rundown of news involving City Therapeutics and Grin Therapeutics, as well as updates from Savara Pharma, Aurion Biotech and Prothena that you may have missed. With only six stock ...

It used to though, with the supercharged V6 HiLux TRD and Aurion TRD, about 10 years ago. You could also get a TRD enhancement pack for the HiLux last year. In the US, however, the TRD brand is ...

The Silky Smooth, But Pricy 2025 GMC Canyon AT4X AEV By Michael Frank Published 3 days ago ...